CytoSorbents Corp. (CTSO) Rating Reiterated by HC Wainwright
CytoSorbents Corp. (NASDAQ:CTSO)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Tuesday.
A number of other analysts have also recently weighed in on CTSO. Maxim Group reissued a “buy” rating and set a $8.00 price objective on shares of CytoSorbents Corp. in a report on Sunday, July 17th. Brean Capital initiated coverage on shares of CytoSorbents Corp. in a report on Tuesday, October 4th. They set a “buy” rating and a $24.00 price objective on the stock. B. Riley initiated coverage on shares of CytoSorbents Corp. in a report on Thursday, October 6th. They set a “buy” rating and a $11.25 price objective on the stock. Finally, Aegis initiated coverage on shares of CytoSorbents Corp. in a report on Wednesday, October 26th. They issued a “buy” rating and a $20.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $15.05.
Shares of CytoSorbents Corp. (NASDAQ:CTSO) opened at 5.60 on Tuesday. The stock has a 50 day moving average of $5.84 and a 200 day moving average of $5.03. CytoSorbents Corp. has a 12-month low of $3.11 and a 12-month high of $8.03. The stock’s market capitalization is $142.45 million.
A hedge fund recently raised its stake in CytoSorbents Corp. stock. BlackRock Institutional Trust Company N.A. boosted its position in shares of CytoSorbents Corp. (NASDAQ:CTSO) by 13.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,955 shares of the company’s stock after buying an additional 3,495 shares during the period. BlackRock Institutional Trust Company N.A. owned 0.12% of CytoSorbents Corp. worth $192,000 as of its most recent filing with the SEC. 6.81% of the stock is owned by institutional investors and hedge funds.
CytoSorbents Corp. Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Stock Ratings for CytoSorbents Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoSorbents Corp. and related stocks with our FREE daily email newsletter.